-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantargia plans Phase 1b/2a trial of nadunolimab plus RAS inhibitor in pancreatic cancer

PUBT·09/30/2026 05:05:01
Cantargia plans Phase 1b/2a trial of nadunolimab plus RAS inhibitor in pancreatic cancer
  • Cantargia flagged new preclinical evidence backing nadunolimab combined with RAS inhibition in pancreatic ductal adenocarcinoma.
  • Results were presented in a poster at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
  • Study showed the combination reshaped the tumor microenvironment, reduced immune suppression, reduced tumor burden versus either approach alone.
  • Data support a planned Phase 1b/2a trial testing nadunolimab with a RAS inhibitor in pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cantargia AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.